vs
Esperion Therapeutics, Inc.（ESPR）与Piedmont Realty Trust, Inc.（PDM）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Piedmont Realty Trust, Inc.的1.2倍（$168.4M vs $143.3M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 0.4%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 0.0%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Piedmont Realty Trust是一家公开上市的房地产投资信托（REIT），主要持有、运营和投资美国高增长大都会区的优质写字楼资产，服务科技、专业服务、医疗等多个行业的企业租户，通过战略资产管理和投资组合优化为利益相关方提供稳定长期回报。
ESPR vs PDM — 直观对比
营收规模更大
ESPR
是对方的1.2倍
$143.3M
营收增速更快
ESPR
高出143.3%
0.4%
两年增速更快
ESPR
近两年复合增速
0.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $143.3M |
| 净利润 | — | $-45.0M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | — |
| 净利率 | — | -31.4% |
| 营收同比 | 143.7% | 0.4% |
| 净利润同比 | — | -27.9% |
| 每股收益（稀释后） | $0.32 | $-0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRPDM
| Q1 26 | — | $143.3M | ||
| Q4 25 | $168.4M | $142.9M | ||
| Q3 25 | $87.3M | $139.2M | ||
| Q2 25 | $82.4M | $140.3M | ||
| Q1 25 | $65.0M | $142.7M | ||
| Q4 24 | $69.1M | $143.2M | ||
| Q3 24 | $51.6M | $139.3M | ||
| Q2 24 | $73.8M | $143.3M |
净利润ESPRPDM
| Q1 26 | — | $-45.0M | ||
| Q4 25 | — | $-43.2M | ||
| Q3 25 | $-31.3M | $-13.5M | ||
| Q2 25 | $-12.7M | $-16.8M | ||
| Q1 25 | $-40.5M | $-10.1M | ||
| Q4 24 | — | $-30.0M | ||
| Q3 24 | $-29.5M | $-11.5M | ||
| Q2 24 | $-61.9M | $-9.8M |
营业利润率ESPRPDM
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — |
净利率ESPRPDM
| Q1 26 | — | -31.4% | ||
| Q4 25 | — | -30.3% | ||
| Q3 25 | -35.9% | -9.7% | ||
| Q2 25 | -15.4% | -12.0% | ||
| Q1 25 | -62.2% | -7.1% | ||
| Q4 24 | — | -20.9% | ||
| Q3 24 | -57.2% | -8.3% | ||
| Q2 24 | -83.9% | -6.8% |
每股收益（稀释后）ESPRPDM
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $0.32 | $-0.34 | ||
| Q3 25 | $-0.16 | $-0.11 | ||
| Q2 25 | $-0.06 | $-0.14 | ||
| Q1 25 | $-0.21 | $-0.08 | ||
| Q4 24 | $-0.14 | $-0.25 | ||
| Q3 24 | $-0.15 | $-0.09 | ||
| Q2 24 | $-0.33 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $2.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $1.5B |
| 总资产 | $465.9M | $4.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRPDM
| Q1 26 | — | $2.3M | ||
| Q4 25 | $167.9M | $731.0K | ||
| Q3 25 | $92.4M | $3.0M | ||
| Q2 25 | $86.1M | $3.3M | ||
| Q1 25 | $114.6M | $2.9M | ||
| Q4 24 | $144.8M | $109.6M | ||
| Q3 24 | $144.7M | $133.6M | ||
| Q2 24 | $189.3M | $138.5M |
总债务ESPRPDM
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
股东权益ESPRPDM
| Q1 26 | — | $1.5B | ||
| Q4 25 | $-302.0M | $1.5B | ||
| Q3 25 | $-451.4M | $1.5B | ||
| Q2 25 | $-433.5M | $1.5B | ||
| Q1 25 | $-426.2M | $1.6B | ||
| Q4 24 | $-388.7M | $1.6B | ||
| Q3 24 | $-370.2M | $1.6B | ||
| Q2 24 | $-344.2M | $1.7B |
总资产ESPRPDM
| Q1 26 | — | $4.0B | ||
| Q4 25 | $465.9M | $4.0B | ||
| Q3 25 | $364.0M | $4.0B | ||
| Q2 25 | $347.1M | $4.0B | ||
| Q1 25 | $324.0M | $4.0B | ||
| Q4 24 | $343.8M | $4.1B | ||
| Q3 24 | $314.1M | $4.1B | ||
| Q2 24 | $352.3M | $4.2B |
负债/权益比ESPRPDM
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | 110.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRPDM
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $140.6M | ||
| Q3 25 | $-4.3M | $35.8M | ||
| Q2 25 | $-31.4M | $50.1M | ||
| Q1 25 | $-22.6M | $3.7M | ||
| Q4 24 | $-35.0M | $198.1M | ||
| Q3 24 | $-35.3M | $42.9M | ||
| Q2 24 | $-7.2M | $66.8M |
自由现金流ESPRPDM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — |
自由现金流率ESPRPDM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — |
资本支出强度ESPRPDM
| Q1 26 | — | 110.3% | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PDM
暂无分部数据
